Skip to main content
SpringerLink
Log in

Healthcare Maintenance in the Patient with Inflammatory Bowel Disease: High-Yield Interventions

  • Chapter
  • First Online:
Inflammatory Bowel Disease

Part of the book series: Clinical Gastroenterology ((CG))

  • 1297 Accesses

Abstract

Healthcare maintenance in inflammatory bowel disease refers to the ongoing health promotion and preventive care that are implemented while managing patients with this chronic illness. In addition to consolidating information about ongoing conventional treatments, queries should involve the domains of complementary medicine and quality of life given the complex nature of this disease. These patients are particularly at increased risk for infection, malignancy, malnutrition, mental illness, and bone disease. Despite its importance, these services are not delivered at the same rates when compared to the general population. Uncertainty around “ownership” of the patient by the primary care provider, anxiety surrounding safety of health maintenance interventions such as vaccination among immunosuppressed populations, and reimbursement concerns contribute to this gap in care. This chapter aims to be a useful primer, for primary care physicians and gastroenterologists, on the value of healthcare maintenance interventions. In addition, we will highlight practical strategies to enable implementation into practice.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 69.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 89.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 159.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Bennett AL, Munkholm P, Andrews JM. Tools for primary care management of inflammatory bowel disease: Do they exist? World J Gastroenterol: WJG. 2015;21(15):4457–65.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Bilal M, Singh S, Lee H, Khosa K, Khehra R, Clarke K. Bridges to excellence quality indicators in inflammatory bowel disease (IBD): differences between IBD and non-IBD gastroenterologists. Ann Gastroenterol Q Publ Hell Soc Gastroenterol. 2017;30(2):192–6.

    Google Scholar 

  3. Reich J, Wasan SK, Farraye FA. Vaccination and health maintenance issues to consider in patients with inflammatory bowel disease. 9.

    Google Scholar 

  4. Zullow S, Farraye FA. Updates on vaccinating the inflammatory bowel disease patient. Expert Rev Gastroenterol Hepatol. 2019;13(3):229–39.

    Article  CAS  PubMed  Google Scholar 

  5. WHO | Improving vaccination demand and addressing hesitancy [Internet]. WHO. World Health Organization; [cited 2020 Nov 2]. Available from: http://www.who.int/immunization/programmes_systems/vaccine_hesitancy/en/.

  6. Vaccine hesitancy: a generation at risk - The Lancet Child & Adolescent Health [Internet]. [cited 2020 Nov 2]. Available from: https://www.thelancet.com/journals/lanchi/article/PIIS2352-4642(19)30092-6/fulltext.

  7. Malhi G, Rumman A, Thanabalan R, Croitoru K, Silverberg MS, Hillary Steinhart A, et al. Vaccination in inflammatory bowel disease patients: attitudes, knowledge, and uptake. J Crohns Colitis. 2015;9(6):439–44.

    Article  PubMed  Google Scholar 

  8. 2013 IDSA Clinical Practice Guideline for Vaccination of the Immunocompromised Host | Clinical Infectious Diseases | Oxford Academic [Internet]. [cited 2020 Nov 2]. Available from: https://academic.oup.com/cid/article/58/3/e44/336537.

  9. Marín AC, Gisbert JP, Chaparro M. Immunogenicity and mechanisms impairing the response to vaccines in inflammatory bowel disease. World J Gastroenterol: WJG. 2015;21(40):11273–81.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  10. Park S-K, Choi CH, Chun J, Lee H, Kim ES, Park JJ, et al. Prevention and management of viral hepatitis in inflammatory bowel disease: a clinical practice guideline by the Korean Association for the Study of Intestinal Diseases. Intest Res. 2020;18(1):18–33.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Health Maintenance Checklists [Internet]. Crohn’s & Colitis Foundation. [cited 2020 Nov 2]. Available from: https://www.crohnscolitisfoundation.org/science-and-professionals/education-resources/health-maintenance-checklists.

  12. Vaccine Types | Vaccines [Internet]. [cited 2020 Nov 2]. Available from: https://www.vaccines.gov/basics/types.

  13. Tinsley A, Navabi S, Williams ED, Liu G, Kong L, Coates MD, et al. Increased risk of influenza and influenza-related complications among 140,480 patients with inflammatory bowel disease. Inflamm Bowel Dis. 2019;25(2):369–76.

    Google Scholar 

  14. Vaccine Effectiveness: How Well Do the Flu Vaccines Work? | CDC [Internet]. 2020 [cited 2020 Nov 2]. Available from: https://www.cdc.gov/flu/vaccines-work/vaccineeffect.htm.

  15. Farraye FA, Melmed GY, Lichtenstein GR, Kane SV. ACG clinical guideline: preventive care in inflammatory bowel disease. Am J Gastroenterol. 2017;112(2):241–58.

    Article  PubMed  Google Scholar 

  16. Nowak GJ, Sheedy K, Bursey K, Smith TM, Basket M. Promoting influenza vaccination: Insights from a qualitative meta-analysis of 14 years of influenza-related communications research by U.S. Centers for Disease Control and Prevention (CDC). Vaccine. 2015;33(24):2741–56.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Long MD, Martin C, Sandler RS, Kappelman MD. Increased risk of pneumonia among patients with inflammatory bowel disease. Am J Gastroenterol. 2013;108(2):240–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. PCV13 (Pneumococcal Conjugate) Vaccine for Adults | For Providers | CDC [Internet]. 2020 [cited 2020 Nov 2]. Available from: https://www.cdc.gov/vaccines/vpd/pneumo/hcp/PCV13-adults.html.

  19. Reich J, Wasan S, Farraye FA. Vaccinating patients with inflammatory bowel disease. Gastroenterol Hepatol. 2016;12(9):540–6.

    Google Scholar 

  20. Serotypes in PPSV23 and PCV13 | PNEUMOVAX®23 (Pneumococcal Vaccine Polyvalent) [Internet]. MerckVaccines.com. [cited 2020 Nov 2]. Available from: https://www.merckvaccines.com/pneumovax23/pneumococcal-serotypes-ppsv23-pcv13/.

  21. EtR for PCV13 use among adults ≥65 years old | CDC [Internet]. 2019 [cited 2020 Nov 2]. Available from: https://www.cdc.gov/vaccines/acip/recs/grade/PCV13-etr.html.

  22. Farshidpour M. Improving immunization strategies in patients with inflammatory bowel disease. Ann Gastroenterol [Internet]. 2019 [cited 2020 Nov 2]; Available from: http://www.annalsgastro.gr/files/journals/1/earlyview/2019/ev-01-2019-15-AG4357-0351.pdf.

  23. PneumoRecs VaxAdvisor: Vaccine Provider App | CDC [Internet]. 2019 [cited 2020 Nov 2]. Available from: https://www.cdc.gov/vaccines/vpd/pneumo/hcp/pneumoapp.html.

  24. Long MD, Martin C, Sandler RS, Kappelman MD. Increased Risk of Herpes Zoster among 108,604 Patients with Inflammatory Bowel Disease. Aliment Pharmacol Ther [Internet]. 2013 Feb [cited 2020 Nov 2];37(4). Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3886551/.

  25. Guillo L, Rabaud C, Choy EH, D’Amico F, Danese S, Ng SC, et al. Herpes zoster and vaccination strategies in inflammatory bowel diseases: a practical guide. Clin Gastroenterol Hepatol [Internet]. 2020 Oct 17 [cited 2020 Nov 2];0(0). Available from: https://www.cghjournal.org/article/S1542-3565(20)31440-3/abstract.

  26. Olivera PA, Lasa JS, Bonovas S, Danese S, Peyrin-Biroulet L. Safety of Janus Kinase inhibitors in patients with inflammatory bowel diseases or other immune-mediated diseases: a systematic review and meta-analysis. Gastroenterology. 2020;158(6):1554–73.e12.

    Google Scholar 

  27. Does Medicare Cover the Vaccine for Shingles? [Internet]. [cited 2020 Nov 2]. Available from: https://www.aarp.org/health/medicare-qa-tool/does-medicare-cover-shingles-shot/.

  28. SHINGRIX (Zoster Vaccine Recombinant, Adjuvanted) Coverage and Coding | GSKPro [Internet]. [cited 2020 Nov 2]. Available from: https://gskpro.com/en-us/products/shingrix/coverage/.

  29. Bojito-Marrero L, Pyrsopoulos N. Hepatitis B and hepatitis C reactivation in the biologic era. J Clin Transl Hepatol. 2014;2(4):240–6.

    PubMed  PubMed Central  Google Scholar 

  30. Hepatitis A Questions and Answers for Health Professionals | CDC [Internet]. [cited 2020 Nov 2]. Available from: https://www.cdc.gov/hepatitis/hav/havfaq.htm.

  31. Ask the Experts: Hepatitis A Vaccines [Internet]. [cited 2020 Nov 2]. Available from: https://www.immunize.org/askexperts/experts_hepa.asp.

  32. Imperatore N, Castiglione F, Rispo A, Sessa A, Caporaso N, Morisco F. Timing strategies of direct-acting antivirals and biologics administration in HCV-infected subjects with inflammatory bowel diseases. Front Pharmacol [Internet]. 2017 Nov 21 [cited 2020 Nov 2];8. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5702483/.

  33. MMR Vaccination | What You Should Know | Measles, Mumps, Rubella | CDC [Internet]. 2019 [cited 2020 Nov 2]. Available from: https://www.cdc.gov/vaccines/vpd/mmr/public/index.html.

  34. 2020 Vax Schedule: Changes to HPV, Pneumococcal Recs | MedPage Today [Internet]. [cited 2020 Nov 2]. Available from: https://www.medpagetoday.com/infectiousdisease/vaccines/84701.

  35. Jacobson DL, Bousvaros A, Ashworth L, Carey R, Shrier LA, Burchett SK, et al. Immunogenicity and Tolerability to Human Papillomavirus-like Particle Vaccine in Girls and Young Women with Inflammatory Bowel Disease. Inflamm Bowel Dis. 2013;19(7):1441–9.

    Article  PubMed  Google Scholar 

  36. Meningococcal Vaccination | CDC [Internet]. 2019 [cited 2020 Nov 2]. Available from: https://www.cdc.gov/vaccines/vpd/mening/index.html.

  37. Fatigue in Inflammatory Bowel Diseases: Etiologies and Management | SpringerLink [Internet]. [cited 2020 Nov 2]. Available from: https://link.springer.com/article/10.1007/s12325-019-01151-w.

  38. Miheller P, Gesztes W, Lakatos PL. Manipulating bone disease in inflammatory bowel disease patients. Ann Gastroenterol Q Publ Hell Soc Gastroenterol. 2013;26(4):296–303.

    Google Scholar 

  39. Rufo PA, Denson LA, Sylvester FA, Szigethy E, Sathya P, Lu Y, et al. Health supervision in the management of children and adolescents with IBD: NASPGHAN recommendations. J Pediatr Gastroenterol Nutr. 2012;55(1):93.

    Article  PubMed  PubMed Central  Google Scholar 

  40. Sgambato D, Gimigliano F, De Musis C, Moretti A, Toro G, Ferrante E, et al. Bone alterations in inflammatory bowel diseases. World J Clin Cases. 2019;7(15):1908–25.

    Article  PubMed  PubMed Central  Google Scholar 

  41. Bone Mass Measurement: What the Numbers Mean | NIH Osteoporosis and Related Bone Diseases National Resource Center [Internet]. [cited 2020 Nov 2]. Available from: https://www.bones.nih.gov/health-info/bone/bone-health/bone-mass-measure.

  42. American Gastroenterological Association medical position statement: Guidelines on osteoporosis in gastrointestinal diseases, This document presents the official recommendations of the American Gastroenterological Association (AGA) Committee on Osteoporosis in Gastrointestinal Disease. It was approved by the Clinical Practice Committee on September 21, 2002, and by the AGA Governing Board on November 1, 2002. Gastroenterology. 2003;124(3):791–4.

    Google Scholar 

  43. Calcium and Vitamin D: Important at Every Age | NIH Osteoporosis and Related Bone Diseases National Resource Center [Internet]. [cited 2020 Nov 2]. Available from: https://www.bones.nih.gov/health-info/bone/bone-health/nutrition/calcium-and-vitamin-d-important-every-age.

  44. The best time to take your calcium supplement [Internet]. Mayo Clinic. [cited 2020 Nov 2]. Available from: https://www.mayoclinic.org/healthy-lifestyle/nutrition-and-healthy-eating/expert-answers/calcium-supplements/faq-20058238.

  45. Bak M, Serdaroglu E, Guclu R. Prophylactic calcium and vitamin D treatments in steroid-treated children with nephrotic syndrome. Pediatr Nephrol Berl Ger. 2006;21(3):350–4.

    Article  Google Scholar 

  46. Taleban S, Li D, Targan SR, Ippoliti A, Brant SR, Cho JH, et al. Ocular manifestations in inflammatory bowel disease are associated with other extra-intestinal manifestations, gender, and genes implicated in other immune-related traits. J Crohns Colitis. 2016;10(1):43–9.

    Article  PubMed  Google Scholar 

  47. Mintz R, Feller ER, Bahr RL, Shah SA. Ocular manifestations of inflammatory bowel disease. Inflamm Bowel Dis. 2004;10(2):135–9.

    Article  PubMed  Google Scholar 

  48. Abegunde AT, Muhammad BH, Ali T. Preventive health measures in inflammatory bowel disease. World J Gastroenterol. 2016;22(34):7625–44.

    Article  PubMed  PubMed Central  Google Scholar 

  49. Keller DS, Windsor A, Cohen R, Chand M. Colorectal cancer in inflammatory bowel disease: review of the evidence. Tech Coloproctology. 2019;23(1):3–13.

    Article  CAS  Google Scholar 

  50. Andersen NN, Jess T. Has the risk of colorectal cancer in inflammatory bowel disease decreased? World J Gastroenterol: WJG. 2013;19(43):7561–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Clarke WT, Feuerstein JD. Colorectal cancer surveillance in inflammatory bowel disease: practice guidelines and recent developments. World J Gastroenterol. 2019;25(30):4148–57.

    Article  PubMed  PubMed Central  Google Scholar 

  52. Wang R, Leong RW. Primary sclerosing cholangitis as an independent risk factor for colorectal cancer in the context of inflammatory bowel disease: a review of the literature. World J Gastroenterol: WJG. 2014;20(27):8783–9.

    PubMed  PubMed Central  Google Scholar 

  53. Andersen NN, Jess T. Has the risk of colorectal cancer in inflammatory bowel disease decreased? World J Gastroenterol: WJG. 2013;19(43):7561–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. Long MD, Kappelman MD, Pipkin CA. Non-melanoma skin cancer in inflammatory bowel disease: a review. Inflamm Bowel Dis. 2011;17(6):1423–7.

    Article  PubMed  Google Scholar 

  55. Long MD, Herfarth HH, Pipkin CA, Porter CQ, Sandler RS, Kappelman MD. Increased risk for non-melanoma skin cancer in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2010;8(3):268–74.

    Google Scholar 

  56. Giagkou E, Saridi M, Albani E, Gaitanis G, Katsanos A, Bechlioulis A, et al. Dermal lesions and skin cancer in patients with inflammatory bowel disease receiving immunosuppressive therapy. Asian Pac J Cancer Prev APJCP. 2018;19(10):2845–51.

    CAS  PubMed  Google Scholar 

  57. Allegretti JR, Barnes EL, Cameron A. Are patients with Inflammatory Bowel Disease on Chronic Immunosuppressive Therapy at increased risk of cervical high-grade dysplasia/cancer? A Meta-Analysis. Inflamm Bowel Dis. 2015;21(5):1089–97.

    Article  PubMed  Google Scholar 

  58. Mikocka-Walus A, Knowles SR, Keefer L, Graff L. Controversies revisited: a systematic review of the comorbidity of depression and anxiety with inflammatory bowel diseases. Inflamm Bowel Dis. 2016;22(3):752–62.

    Article  PubMed  Google Scholar 

  59. Prevalence of Anxiety and Depression in Patients with Inflammatory Bowel Disease [Internet]. [cited 2020 Nov 8]. Available from: https://www.hindawi.com/journals/cjgh/2017/6496727/.

  60. Kane SV. Health maintenance assessment for patients with inflammatory bowel disease. Gastroenterol Hepatol. 2017;13(8):500–3.

    Google Scholar 

  61. Bennebroek Evertsz F, Sprangers MAG, Sitnikova K, Stokkers PCF, Ponsioen CY, Bartelsman JFWM, et al. Effectiveness of cognitive-behavioral therapy on quality of life, anxiety, and depressive symptoms among patients with inflammatory bowel disease: a multicenter randomized controlled trial. J Consult Clin Psychol 2017;85(9):918–925.

    Google Scholar 

  62. McCombie AM, Mulder RT, Gearry RB. Psychotherapy for inflammatory bowel disease: a review and update. J Crohns Colitis. 2013;7(12):935–49.

    Article  PubMed  Google Scholar 

  63. Nocerino A, Nguyen A, Agrawal M, Mone A, Lakhani K, Swaminath A. Fatigue in inflammatory bowel diseases: etiologies and management. Adv Ther. 2020;37(1):97–112.

    Article  PubMed  Google Scholar 

  64. Santus P, Radovanovic D, Raiteri D, Pini S, Spagnolo G, Maconi G, et al. The effect of a multidisciplinary approach for smoking cessation in patients with Crohn’s disease: Results from an observational cohort study. Tob Induc Dis [Internet]. 2020 Apr 2 [cited 2020 Nov 8];18. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7177387/.

  65. Severs M, van Erp SJH, van der Valk ME, Mangen MJJ, Fidder HH, van der Have M, et al. Smoking is associated with extra-intestinal manifestations in inflammatory bowel disease. J Crohns Colitis. 2016;10(4):455–61.

    Article  CAS  PubMed  Google Scholar 

  66. Larzelere MM, Williams DE. Promoting smoking cessation. Am Fam Physician. 2012;85(6):591–8.

    PubMed  Google Scholar 

  67. Pharmacologic Product Guide: FDA-Approved Medications for Smoking Cessation. 2.

    Google Scholar 

  68. Larzelere MM, Williams DE. Promoting smoking cessation. Am Fam Physician. 2012;85(6):591–8.

    PubMed  Google Scholar 

  69. de Vries JHM, Dijkhuizen M, Tap P, Witteman BJM. Patient’s dietary beliefs and behaviours in inflammatory bowel disease. Dig Dis Basel Switz. 2019;37(2):131–9.

    Google Scholar 

  70. Swaminath A, Feathers A, Ananthakrishnan A, Falzon L, Ferry SL. Systematic review with meta-analysis: enteral nutrition therapy for the induction of remission in pediatric Crohn’s Disease. Aliment Pharmacol Ther. 2017;46(7):645–56.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  71. Lewis JD. The role of diet in inflammatory bowel disease. Gastroenterol Hepatol. 2016;12(1):51–3.

    Google Scholar 

  72. Sood A, Ahuja V, Kedia S, Midha V, Mahajan R, Mehta V, et al. Diet and inflammatory bowel disease: The Asian Working Group guidelines. Indian J Gastroenterol. 2019;38(3):220–46.

    Article  PubMed  PubMed Central  Google Scholar 

  73. Gkikas K, Gerasimidis K, Milling S, Ijaz UZ, Hansen R, Russell RK. Dietary strategies for maintenance of clinical remission in inflammatory bowel diseases: are we there yet? Nutrients [Internet]. 2020 Jul 7 [cited 2020 Nov 8];12(7). Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7400838/.

  74. Trial of Specific Carbohydrate and Mediterranean Diets to Induce Remission of Crohn’s Disease - Full Text View - ClinicalTrials.gov [Internet]. [cited 2020 Nov 8]. Available from: https://clinicaltrials.gov/ct2/show/NCT03058679.

  75. Pan Y, Liu Y, Guo H, Jabir MS, Liu X, Cui W, et al. Associations between folate and vitamin B12 levels and inflammatory bowel disease: a meta-analysis. nutrients [Internet]. 2017 Apr 13 [cited 2020 Nov 8];9(4). Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5409721/.

  76. Yakut M, Ustün Y, Kabaçam G, Soykan I. Serum vitamin B12 and folate status in patients with inflammatory bowel diseases. Eur J Intern Med. 2010;21(4):320–3.

    Article  CAS  PubMed  Google Scholar 

  77. Gomollón F, Gargallo CJ, Muñoz JF, Vicente R, Lue A, Mir A, et al. Oral cyanocobalamin is effective in the treatment of vitamin B12 deficiency in Crohn’s Disease. Nutrients. 2017;20:9(3).

    Google Scholar 

  78. Langan RC, Goodbred AJ. Vitamin B12 deficiency: recognition and management. Am Fam Physician. 2017;96(6):384–9.

    PubMed  Google Scholar 

  79. Vitamin and Mineral Supplementation [Internet]. Crohn’s & Colitis Foundation. [cited 2020 Nov 8]. Available from: https://www.crohnscolitisfoundation.org/diet-and-nutrition/supplementation.

  80. Kaitha S, Bashir M, Ali T. Iron deficiency anemia in inflammatory bowel disease. World J Gastrointest Pathophysiol. 2015;6(3):62–72.

    Article  PubMed  PubMed Central  Google Scholar 

  81. Niepel D, Klag T, Malek NP, Wehkamp J. Practical guidance for the management of iron deficiency in patients with inflammatory bowel disease. Ther Adv Gastroenterol [Internet]. 2018 Apr 26 [cited 2020 Nov 8];11. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5946590/.

  82. Gargallo-Puyuelo CJ, Alfambra E, García-Erce JA, Gomollon F. Iron treatment may be difficult in inflammatory diseases: inflammatory bowel disease as a Paradigm. Nutrients [Internet]. 2018 Dec 11 [cited 2020 Nov 8];10(12). Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6316243/.

  83. Wang C, Graham DJ, Kane RC, Xie D, Wernecke M, Levenson M, et al. Comparative risk of anaphylactic reactions associated with intravenous iron products. JAMA. 2015;314(19):2062–8.

    Article  CAS  PubMed  Google Scholar 

  84. Yin K, Agrawal DK. Vitamin D and inflammatory diseases. J Inflamm Res. 2014;7:69–87.

    CAS  PubMed  PubMed Central  Google Scholar 

  85. Fletcher J, Cooper SC, Ghosh S, Hewison M. The role of vitamin D in inflammatory bowel disease: mechanism to management. Nutrients [Internet]. 2019 May 7 [cited 2020 Nov 8];11(5). Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6566188/.

  86. Hlavaty T, Krajcovicova A, Payer J. Vitamin D therapy in inflammatory bowel diseases: who, in what form, and how much? J Crohns Colitis. 2015;9(2):198–209.

    Article  PubMed  Google Scholar 

  87. Shrestha MP, Ruel J, Taleban S. Healthcare maintenance in elderly patients with inflammatory bowel disease. Ann Gastroenterol. 2017;30(3):273–86.

    PubMed  PubMed Central  Google Scholar 

  88. Ananthakrishnan AN, McGinley EL. Infection-related hospitalizations are associated with increased mortality in patients with inflammatory bowel diseases. J Crohns Colitis. 2013;7(2):107–12.

    Article  PubMed  Google Scholar 

  89. Asscher VER, E van der Meulen-de Jong A, Mooijaart SP. The challenges of managing inflammatory bowel diseases in older patients. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2020;18(7):1648–9.

    Google Scholar 

  90. Zakai NA, Katz R, Hirsch C, Shlipak MG, Chaves PHM, Newman AB, et al. A prospective study of anemia status, hemoglobin concentration, and mortality in an elderly cohort: the Cardiovascular Health Study. Arch Intern Med. 2005;165(19):2214–20.

    Article  PubMed  Google Scholar 

  91. Chan W, Chen A, Tiao D, Selinger C, Leong R. Medication adherence in inflammatory bowel disease. Intest Res. 2017;15(4):434–45.

    Article  PubMed  PubMed Central  Google Scholar 

  92. Tiao DK, Chan W, Jeganathan J, Chan JT, Perry J, Selinger CP, et al. Inflammatory bowel disease pharmacist adherence counseling improves medication adherence in Crohn’s Disease and Ulcerative Colitis. Inflamm Bowel Dis. 2017;23(8):1257–61.

    Article  PubMed  Google Scholar 

  93. Romberg-Camps MJL, Bol Y, Dagnelie PC, Hesselink-van de Kruijs MAM, Kester ADM, Engels LGJB, et al. Fatigue and health-related quality of life in inflammatory bowel disease: results from a population-based study in the Netherlands: the IBD-South Limburg cohort. Inflamm Bowel Dis 2010;16(12):2137–2147.

    Google Scholar 

  94. Targownik LE, Sexton KA, Bernstein MT, Beatie B, Sargent M, Walker JR, et al. The relationship among perceived stress, symptoms, and inflammation in persons with inflammatory bowel disease. Am J Gastroenterol. 2015;110(7):1001–12. quiz 1013

    Article  CAS  PubMed  Google Scholar 

  95. Lin SC, Cheifetz AS. The use of complementary and alternative medicine in patients with inflammatory bowel disease. Gastroenterol Hepatol. 2018;14(7):415–25.

    Google Scholar 

  96. RL Nahin, Barnes P, Stussman B. Expenditures on Complementary Health Approaches: United States, 2012 [Internet]. Expenditures on complementary health approaches: United States 2012. 2016 [cited 2020 Nov 1]. Available from: https://www.nccih.nih.gov/research/expenditures-on-complementary-health-approaches-united-states-2012.

  97. McLean LP, Cross RK. Adverse events in IBD: to stop or continue immune suppressant and biologic treatment. Expert Rev Gastroenterol Hepatol. 2014;8(3):223–40.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  98. Naftali T, Bar-Lev Schleider L, Dotan I, Lansky EP, Sklerovsky Benjaminov F, Konikoff FM. Cannabis induces a clinical response in patients with Crohn’s disease: a prospective placebo-controlled study. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2013;11(10):1276–1280.e1.

    Google Scholar 

  99. Goyal H, Singla U, Gupta U, May E. Role of cannabis in digestive disorders. Eur J Gastroenterol Hepatol. 2017;29(2):135–43.

    Article  CAS  PubMed  Google Scholar 

  100. Naftali T. An overview of cannabis based treatment in Crohn’s disease. Expert Rev Gastroenterol Hepatol. 2020;14(4):253–7.

    Article  CAS  PubMed  Google Scholar 

  101. Quezada SM, Cross RK. Cannabis and turmeric as complementary treatments for IBD and other digestive diseases. Curr Gastroenterol Rep. 2019;21(2):2.

    Article  PubMed  Google Scholar 

  102. Ahmed W, Katz S. Therapeutic use of cannabis in inflammatory bowel disease. Gastroenterol Hepatol. 2016;12(11):668–79.

    Google Scholar 

  103. Sumariwalla PF, Gallily R, Tchilibon S, Fride E, Mechoulam R, Feldmann M. A novel synthetic, nonpsychoactive cannabinoid acid (HU-320) with antiinflammatory properties in murine collagen-induced arthritis. Arthritis Rheum. 2004;50(3):985–98.

    Article  CAS  PubMed  Google Scholar 

  104. Naftali T, Lev LB, Yablecovitch D, Yablekovitz D, Half E, Konikoff FM. Treatment of Crohn’s disease with cannabis: an observational study. Isr Med Assoc J IMAJ. 2011;13(8):455–8.

    PubMed  Google Scholar 

  105. Swaminath A, Berlin EP, Cheifetz A, Hoffenberg E, Kinnucan J, Wingate L, et al. The role of cannabis in the management of inflammatory bowel disease: a review of clinical, scientific, and regulatory information. Inflamm Bowel Dis. 2019. 21;25(3):427–35.

    Google Scholar 

  106. Naftali T, Mechulam R, Marii A, Gabay G, Stein A, Bronshtain M, et al. Low-dose cannabidiol is safe but not effective in the treatment for Crohn’s Disease, a randomized controlled trial. Dig Dis Sci. 2017;62(6):1615–20.

    Article  CAS  PubMed  Google Scholar 

  107. UEG - United European Gastroenterology [Internet]. [cited 2020 Nov 8]. Available from: https://ueg.eu/library/cannabis-induces-clinical-response-but-no-endoscopic-response-in-crohns-disease-patients/180241.

  108. Rubino T, Zamberletti E, Parolaro D. Adolescent exposure to cannabis as a risk factor for psychiatric disorders. J Psychopharmacol Oxf Engl. 2012;26(1):177–88.

    Article  CAS  Google Scholar 

  109. Hejazi RA, McCallum RW. Review article: cyclic vomiting syndrome in adults--rediscovering and redefining an old entity. Aliment Pharmacol Ther. 2011;34(3):263–73.

    Article  CAS  PubMed  Google Scholar 

  110. Storr M, Devlin S, Kaplan GG, Panaccione R, Andrews CN. Cannabis use provides symptom relief in patients with inflammatory bowel disease but is associated with worse disease prognosis in patients with Crohn’s disease. Inflamm Bowel Dis. 2014;20(3):472–80.

    Article  PubMed  Google Scholar 

  111. Health CO on S and. Smoking and Tobacco Use; Electronic Cigarettes [Internet]. Centers for Disease Control and Prevention. 2020 [cited 2020 Nov 8]. Available from: https://www.cdc.gov/tobacco/basic_information/e-cigarettes/severe-lung-disease.html.

  112. Torres J, Ellul P, Langhorst J, Mikocka-Walus A, Barreiro-de Acosta M, Basnayake C, et al. European Crohn’s and colitis organisation topical review on complementary medicine and psychotherapy in inflammatory bowel disease. J Crohns Colitis. 2019;13(6):673–85e.

    Google Scholar 

  113. Medical Cannabis [Internet]. Crohn’s & Colitis Foundation. [cited 2020 Nov 1]. Available from: https://www.crohnscolitisfoundation.org/complementary-medicine/medical-cannabis.

Download references

Author information

Authors and Affiliations

  1. Division of Gastroenterology at Lenox Hill Hospital, Northwell Health, New York, NY, USA

    Isabel Roitman, Anjali Mone & Arun Swaminath

Authors
  1. Isabel Roitman
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Anjali Mone
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Arun Swaminath
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Arun Swaminath .

Editor information

Editors and Affiliations

  1. Zucker School of Medicine at Hofstra/Northwell, Mather Gastroenterology, Port Jefferson, NY, USA

    Ramona Rajapakse

Rights and permissions

Reprints and permissions

Copyright information

© 2021 The Author(s), under exclusive license to Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Roitman, I., Mone, A., Swaminath, A. (2021). Healthcare Maintenance in the Patient with Inflammatory Bowel Disease: High-Yield Interventions. In: Rajapakse, R. (eds) Inflammatory Bowel Disease. Clinical Gastroenterology. Humana, Cham. https://doi.org/10.1007/978-3-030-81780-0_7

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-81780-0_7

  • Published:

  • Publisher Name: Humana, Cham

  • Print ISBN: 978-3-030-81779-4

  • Online ISBN: 978-3-030-81780-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation